Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Q32 Bio (QTTB) over the last 3 years, with Q3 2025 value amounting to $106737.0.

  • Q32 Bio's Gains from Sales and Divestitures changed N/A to $106737.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $106737.0, marking a year-over-year change of. This contributed to the annual value of $373519.0 for FY2023, which is 24944.24% up from last year.
  • Latest data reveals that Q32 Bio reported Gains from Sales and Divestitures of $106737.0 as of Q3 2025.
  • In the past 5 years, Q32 Bio's Gains from Sales and Divestitures registered a high of $373519.0 during Q4 2023, and its lowest value of $87140.0 during Q1 2022.
  • For the 3-year period, Q32 Bio's Gains from Sales and Divestitures averaged around $170575.9, with its median value being $106890.0 (2022).
  • Examining YoY changes over the last 5 years, Q32 Bio's Gains from Sales and Divestitures showed a top increase of 24944.24% in 2023 and a maximum decrease of 12323.27% in 2023.
  • Quarter analysis of 3 years shows Q32 Bio's Gains from Sales and Divestitures stood at $106890.0 in 2022, then surged by 249.44% to $373519.0 in 2023, then plummeted by 71.42% to $106737.0 in 2025.
  • Its last three reported values are $106737.0 in Q3 2025, $373519.0 for Q4 2023, and $281117.0 during Q3 2023.